|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2000-7-27
|
|
pubmed:abstractText |
Arsenic trioxide, like all-trans-retinoic acid (RA), induces differentiation of acute promyelocytic leukemia (APL) cells in vivo. Treatment of APL patients with all-trans RA is commonly associated with leukocytosis, and approximately 50% of patients develop the RA syndrome. We reviewed our clinical experience with arsenic trioxide to determine the incidence of these two phenomena.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2620-5
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10893295-Antineoplastic Agents,
pubmed-meshheading:10893295-Arsenicals,
pubmed-meshheading:10893295-Dyspnea,
pubmed-meshheading:10893295-Fever,
pubmed-meshheading:10893295-Humans,
pubmed-meshheading:10893295-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:10893295-Leukocytosis,
pubmed-meshheading:10893295-Oxides,
pubmed-meshheading:10893295-Pleural Effusion,
pubmed-meshheading:10893295-Syndrome,
pubmed-meshheading:10893295-Tretinoin
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
|
|
pubmed:affiliation |
Leukemia and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
